TR200103046T2 - IL5 aktivitesini düşürmek için yöntem. - Google Patents
IL5 aktivitesini düşürmek için yöntem.Info
- Publication number
- TR200103046T2 TR200103046T2 TR2001/03046T TR200103046T TR200103046T2 TR 200103046 T2 TR200103046 T2 TR 200103046T2 TR 2001/03046 T TR2001/03046 T TR 2001/03046T TR 200103046 T TR200103046 T TR 200103046T TR 200103046 T2 TR200103046 T2 TR 200103046T2
- Authority
- TR
- Turkey
- Prior art keywords
- modified
- present
- production
- nucleic acid
- acid fragments
- Prior art date
Links
- 102000000743 Interleukin-5 Human genes 0.000 title abstract 10
- 108010002616 Interleukin-5 Proteins 0.000 title abstract 10
- 238000000034 method Methods 0.000 title abstract 6
- 230000000694 effects Effects 0.000 title abstract 2
- 229940100602 interleukin-5 Drugs 0.000 abstract 9
- 150000007523 nucleic acids Chemical group 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 2
- 210000003979 eosinophil Anatomy 0.000 abstract 2
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 230000016784 immunoglobulin production Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5409—IL-5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Mevcut bulus özelligi eosinofil lökositlerinin yüksek seviyede olmasi olan rahatsizliklarin, yani astim ve diger kronik alerjik hastaliklar gibi rahatsizliklarin, tedavisi ve önlenmesindeki gelismelerle ilgilidir. Interlökin 5'e (IL5) karsi antikor üretimi saglayarak IL5'i düsürmek ve böylece eosinofillerin aktivite seviyesini düsürmek için bir yöntem saglanmaktadir. Bulus ayrica bu yöntemde yararli olan modifiye IL5 üretimi için yöntemler ve bu modifiye IL5'leri saglar. Mevcut bulus ayrica modifiye IL5 kodlayan nükleik asit fragmanlari ve bu nükleik asit fragmanlarini içeren vektörleri ve bunlarla dönüstürülen alici hücreleri ve hücre çizgilerini de kapsar. Bulus ayrica bulusun yönteminde yararli olan IL5 analoglarinin belirlenmesi için bir yöntem ve modifiye IL5 içeren veya IL5 analoglarini kodlayan nükleik asitler içeren bilesimler saglar. Mevcut bulusun tercih edilen uygulanmasi, otolog IL5'e baglanan çapraz-reaktiv antikorlarin üretimini indüklemek için yabanci DEVAMI VAR
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA199900552 | 1999-04-23 | ||
US13281199P | 1999-05-06 | 1999-05-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
TR200103046T2 true TR200103046T2 (tr) | 2002-06-21 |
Family
ID=26064209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2001/03046T TR200103046T2 (tr) | 1999-04-23 | 2000-04-19 | IL5 aktivitesini düşürmek için yöntem. |
Country Status (19)
Country | Link |
---|---|
US (2) | US7285273B1 (tr) |
EP (1) | EP1173573A1 (tr) |
JP (1) | JP2002543098A (tr) |
KR (1) | KR20020084841A (tr) |
CN (1) | CN1355846A (tr) |
AU (1) | AU777952B2 (tr) |
CA (1) | CA2370391A1 (tr) |
CZ (1) | CZ20013709A3 (tr) |
EA (1) | EA200101125A1 (tr) |
EE (1) | EE200100552A (tr) |
HR (1) | HRP20010824A2 (tr) |
HU (1) | HUP0200958A3 (tr) |
IL (1) | IL145786A0 (tr) |
MX (1) | MXPA01010625A (tr) |
NO (1) | NO20015021L (tr) |
PL (1) | PL351986A1 (tr) |
SK (1) | SK14832001A3 (tr) |
TR (1) | TR200103046T2 (tr) |
WO (1) | WO2000065058A1 (tr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9706957D0 (en) | 1997-04-05 | 1997-05-21 | Smithkline Beecham Plc | Formulation |
GB9820525D0 (en) | 1998-09-21 | 1998-11-11 | Allergy Therapeutics Ltd | Formulation |
US6913749B2 (en) | 1998-11-02 | 2005-07-05 | Resistentia Pharmaceuticals Ab | Immunogenic polypeptides for inducing anti-self IgE responses |
GB0000891D0 (en) * | 2000-01-14 | 2000-03-08 | Allergy Therapeutics Ltd | Formulation |
US7094409B2 (en) | 2001-01-19 | 2006-08-22 | Cytos Biotechnology Ag | Antigen arrays for treatment of allergic eosinophilic diseases |
US7097837B2 (en) | 2001-02-19 | 2006-08-29 | Pharmexa A/S | Synthetic vaccine agents |
MXPA04003901A (es) * | 2001-11-07 | 2004-07-08 | Cytos Biotechnology Ag | Disposiciones de antigenos para el tratamiento de enfermedades eosinofilicas alergicas. |
CN1321695C (zh) * | 2001-11-07 | 2007-06-20 | 赛托斯生物技术公司 | 用于治疗变应性嗜酸细胞性疾病的展示il-5、il-3或嗜酸细胞活化趋化因子的抗原阵列 |
WO2003042244A2 (en) * | 2001-11-16 | 2003-05-22 | Pharmexa A/S | Immunogenic mimetics of multimer proteins with promiscuous t cell epitope inserts |
AU2003260748A1 (en) * | 2002-08-30 | 2004-03-19 | Glaxo Group Limited | Il-14 vaccine for the treatment of asthma and atopic disorders |
US20060147417A1 (en) * | 2002-08-30 | 2006-07-06 | Claire Ashman | Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use |
JP2007525436A (ja) * | 2003-03-24 | 2007-09-06 | マーシア・ファーマ・インコーポレイテッド | 炎症症状を処置および予防するための方法および組成物 |
CN103091499B (zh) * | 2013-01-23 | 2015-07-08 | 三峡大学 | 一种肿瘤标志物钙网蛋白检测试剂盒的制备及应用 |
CA2900824A1 (en) * | 2013-02-22 | 2014-08-28 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized major histocompatibility complex |
CN105188358B (zh) * | 2013-03-11 | 2018-01-26 | 瑞泽恩制药公司 | 表达嵌合的主要组织相容性复合物(mhc)i类分子的转基因小鼠 |
CN112225807B (zh) * | 2020-10-30 | 2021-09-07 | 上海洛启生物医药技术有限公司 | 抗il5纳米抗体及其应用 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5096704A (en) | 1988-11-03 | 1992-03-17 | Schering Corporation | Method of treating eosinophilia |
FR2677654B1 (fr) | 1991-06-17 | 1995-11-17 | Pasteur Merieux Serums Vacc | Composes a effet immunogene anti-cytokine, a effet immunogene anticytostatique ou a effet vaccinal anti-infection a hiv. |
WO1993023076A1 (en) | 1992-05-20 | 1993-11-25 | The Johns-Hopkins University | Alternative receptor therapy |
US5616488A (en) | 1992-12-07 | 1997-04-01 | Ribozyme Pharmaceuticals, Inc. | IL-5 targeted ribozymes |
DK96493D0 (da) * | 1993-08-26 | 1993-08-26 | Mouritsen Og Elsner Aps | Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden |
PT735893E (pt) | 1993-09-14 | 2009-03-06 | Pharmexa Inc | Péptidos que se ligam aos alelos pan dr para aumentar a resposta imunitária |
CA2186595A1 (en) * | 1994-03-28 | 1995-10-05 | Chang Yi Wang | Synthetic peptide based immunogens for the treatment of allergy |
AUPO005496A0 (en) | 1996-05-24 | 1996-06-13 | Bresagen Limited | An interleukin-5 antagonist |
ATE196297T1 (de) * | 1994-05-18 | 2000-09-15 | Synthetic Peptides Inc | Heterodimere trägerzusammensetzung von immunogenen polypeptiden und verfahren zu deren verwendung |
GB9412230D0 (en) | 1994-06-17 | 1994-08-10 | Celltech Ltd | Interleukin-5 specific recombiant antibodies |
WO1997000321A1 (en) * | 1995-06-14 | 1997-01-03 | Commonwealth Scientific And Industrial Research Organisation | Immune response modulators and uses therefor |
CA2751712C (en) | 1996-10-23 | 2016-11-22 | The Trustees Of The University Of Pennsylvania | Immunotherapy and improved vaccines |
AUPO390396A0 (en) | 1996-11-29 | 1996-12-19 | Csl Limited | Novel promiscuous T helper cell epitopes |
EP1005374B1 (en) | 1997-01-22 | 2007-04-18 | Zycos Inc. | Microparticles for delivery of nucleic acid |
WO1998047923A1 (en) | 1997-04-18 | 1998-10-29 | Tanox Biosystems, Inc. | Il-5r antagonists for treatment of inflammation, asthma and other allergic diseases |
US7005498B1 (en) * | 1998-10-05 | 2006-02-28 | Pharmexa A/S | Methods for therapeutic vaccination |
-
2000
- 2000-04-19 HU HU0200958A patent/HUP0200958A3/hu unknown
- 2000-04-19 US US09/980,916 patent/US7285273B1/en not_active Expired - Fee Related
- 2000-04-19 SK SK1483-2001A patent/SK14832001A3/sk unknown
- 2000-04-19 CA CA002370391A patent/CA2370391A1/en not_active Abandoned
- 2000-04-19 IL IL14578600A patent/IL145786A0/xx unknown
- 2000-04-19 EE EEP200100552A patent/EE200100552A/xx unknown
- 2000-04-19 JP JP2000614393A patent/JP2002543098A/ja active Pending
- 2000-04-19 MX MXPA01010625A patent/MXPA01010625A/es unknown
- 2000-04-19 CZ CZ20013709A patent/CZ20013709A3/cs unknown
- 2000-04-19 TR TR2001/03046T patent/TR200103046T2/tr unknown
- 2000-04-19 PL PL00351986A patent/PL351986A1/xx not_active Application Discontinuation
- 2000-04-19 WO PCT/DK2000/000205 patent/WO2000065058A1/en not_active Application Discontinuation
- 2000-04-19 CN CN00806367A patent/CN1355846A/zh active Pending
- 2000-04-19 AU AU41008/00A patent/AU777952B2/en not_active Ceased
- 2000-04-19 EP EP00920423A patent/EP1173573A1/en not_active Ceased
- 2000-04-19 KR KR1020017013585A patent/KR20020084841A/ko not_active Application Discontinuation
- 2000-04-19 EA EA200101125A patent/EA200101125A1/ru unknown
- 2000-04-21 US US09/556,818 patent/US6746669B1/en not_active Expired - Fee Related
-
2001
- 2001-10-15 NO NO20015021A patent/NO20015021L/no not_active Application Discontinuation
- 2001-11-08 HR HR20010824A patent/HRP20010824A2/hr not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO20015021L (no) | 2001-12-21 |
JP2002543098A (ja) | 2002-12-17 |
EP1173573A1 (en) | 2002-01-23 |
US7285273B1 (en) | 2007-10-23 |
CA2370391A1 (en) | 2000-11-02 |
CZ20013709A3 (cs) | 2002-11-13 |
HUP0200958A3 (en) | 2004-11-29 |
AU777952B2 (en) | 2004-11-04 |
PL351986A1 (en) | 2003-07-14 |
AU4100800A (en) | 2000-11-10 |
CN1355846A (zh) | 2002-06-26 |
EA200101125A1 (ru) | 2002-04-25 |
HRP20010824A2 (en) | 2002-12-31 |
HUP0200958A2 (en) | 2002-06-29 |
NO20015021D0 (no) | 2001-10-15 |
SK14832001A3 (sk) | 2003-02-04 |
WO2000065058A1 (en) | 2000-11-02 |
KR20020084841A (ko) | 2002-11-11 |
IL145786A0 (en) | 2002-07-25 |
MXPA01010625A (es) | 2003-09-04 |
EE200100552A (et) | 2002-12-16 |
US6746669B1 (en) | 2004-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR200103046T2 (tr) | IL5 aktivitesini düşürmek için yöntem. | |
Ouaissi et al. | Fibronectin receptors on Trypanosoma cruzi trypomastigotes and their biological function | |
NO2017038I1 (no) | Adalimumab - Forlenget SPC | |
WO1998021334A3 (en) | Antibody mg1 recognizing a small subset of human hematopoietic cells | |
Watson et al. | The purification and quantitation of helper T cell-replacing factors secreted by murine spleen cells activated by concanavalin A | |
BRPI0516572A (pt) | métodos e composições para melhorar a produção de proteìnas recombinantes | |
DE60031419D1 (de) | Zusammensetzungen und verfahren für verbesserte zellkultur | |
ATE400587T1 (de) | Gegen das prostata-stammzellantigen (psca) gerichtete antikörper und deren verwendung | |
PL343245A1 (en) | Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses | |
KR890001581A (ko) | 조직인자 억제제 | |
BURTON et al. | Actin detected in mouse neuroblastoma cells by binding of heavy meromyosin | |
Sato et al. | The 70-kDa major DNA-compacting protein of the chloroplast nucleoid is sulfite reductase | |
Sanz et al. | The complete primary structure of the boar spermadhesin AQN‐1, a carbohydrate‐binding protein involved in fertilization | |
Mochizuki et al. | Biochemical and biologic characterization of lymphocyte regulatory molecules. IV. Purification of Interleukin 2 from a murine T cell lymphoma. | |
Valisena et al. | Purification and characterization of three separate bacteriolytic enzymes excreted by Staphylococcus aureus, Staphylococcus simulans, and Staphylococcus saprophyticus | |
MXPA02008239A (es) | Gen humano de la esquizofrenia. | |
Coronel et al. | Catalytic properties of the sperm‐specific lactate dehydrogenase (LDH X or C4) from different species | |
Cinader et al. | An alpha-globulin allotype in the mouse (MuB 1) | |
Cesbron et al. | Human coumarin prothrombin | |
Brown et al. | The synthesis and processing of β-glucuronidase in normal and egasyn deficient mouse kidney | |
Astedt et al. | Time-related release of various molecular forms of urokinase in tissue culture | |
Meisler et al. | Localization of the uroporphyrinogen I synthase locus to human chromosome region 11q13→ qter and interconversion of enzyme isomers | |
Malhotra | Purification and characterization of dicoumarol-induced prothrombins. II. Barium oxalate atypical (5-Gla) variant | |
ATE80912T1 (de) | Menschliche proteine des chinolinesterase-typs und ihre herstellung. | |
RU94043769A (ru) | Способ повышения продукции протеина с, способ повышения уровня его модификации |